RACURA ONCOLOGY ORDINARY (RAC) Short Interest
RACURA ONCOLOGY ORDINARY (ASX:RAC) had 0.01% of shares reported as short positions as of 16 July 2026, representing 19,354 shares. RACURA ONCOLOGY ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Racura Oncology
Racura Oncology is a Phase 3 clinical biopharmaceutical company focused on developing cancer therapeutics. Their lead asset, RCDS1 (E,E-bisantrene), targets G4-DNA & RNA binding to inhibit MYC, a key cancer growth regulator, and is being advanced in multiple oncology indications.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4RAC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Racura Oncology
Latest RAC news
All news- Racura Oncology (ASX:RAC) Edges Higher: Could This ASX Cancer-Therapy Stock Be One to Watch? - Kalkine
googlenews
- Notification of cessation of securities - RAC
asx
- Racura to Present CPACS Data at GCOS 2026
asx
- Racura Oncology Announces Auckland Investor Briefing and Presentation at 20th Bioshares Biotech Summit in August 2026
kalkine
- Racura Oncology New Zealand Investor Events
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss RAC
Start a research thread or post the first pulse update